EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

CCL17 / TARC in autoimmunity and inflammation—not just a T‐cell chemokine

Tanya J Lupancu iD, Mahtab Eivazitork iD, John A Hamilton iD, Adrian A Achuthan iD, Kevin M-C Lee iD

Immunology & Cell Biology · 2023

DOI: 10.1111/imcb.12644 ↗

At a glance

Übersichtsarbeit in Immunology & Cell Biology, 2023. Written by Tanya J Lupancu and 4 co-authors. Institution: Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia. Major MEDLINE topics: Autoimmunity, Receptors, Chemokine. Cited 69 times so far (Crossref); 89 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: University of Melbourne.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Chemokine (C–C) ligand 17 (CCL17) was first identified as thymus‐ and activation‐regulated chemokine when it was found to be constitutively expressed in the thymus and identified as a T‐cell chemokine. This chemoattractant molecule has subsequently been found at elevated levels in a range of autoimmune and inflammatory diseases, as well as in cancer. CCL17 is a C–C chemokine receptor type 4 (CCR4) ligand, with chemokine (C–C) ligand 22 being the other major ligand and, as CCR4 is highly expressed on helper T cells, CCL17 can play a role in T‐cell–driven diseases, usually considered to be via its chemotactic activity on T helper 2 cells; however, given that CCR4 is also expressed by other cell types and there is elevated expression of CCL17 in many diseases, a broader CCL17 biology is suggested. In this review, we summarize the biology of CCL17, its regulation and its potential contribution to the pathogenesis of various preclinical models. Reference is made, for example, to recent literature indicating a role for CCL17 in the control of pain as part of a granulocyte macrophage–colony‐stimulating factor/CCL17 pathway in lymphocyte‐independent models and thus not as a T‐cell chemokine. The review also discusses the potential for CCL17 to be a biomarker and a therapeutic target in human disorders.

Subjects

MeSH terms (MEDLINE)

AutoimmunityReceptors, ChemokineHumansLigandsChemokine CCL17ChemokinesInflammation

Author keywords

AutoimmunityCCL17chemokineinflammationpaintherapy

Substances

LigandsReceptors, ChemokineChemokine CCL17ChemokinesCCL17 protein, human

Authors and institutions

  • Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
  • Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, St Albans, VIC, Australia.

ORCID profiles: Tanya J Lupancu, Mahtab Eivazitork, John A Hamilton, Adrian A Achuthan, Kevin M-C Lee

Funding

  • University of Melbourne

Cite

APA

Lupancu, T. J., Eivazitork, M., Hamilton, J. A., Achuthan, A. A., & Lee, K. M. (2023). CCL17 / TARC in autoimmunity and inflammation—not just a T‐cell chemokine. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12644

Vancouver

Lupancu TJ, Eivazitork M, Hamilton JA, Achuthan AA, Lee KM. CCL17 / TARC in autoimmunity and inflammation—not just a T‐cell chemokine. Immunology & Cell Biology. 2023. doi:10.1111/imcb.12644

BibTeX
@article{Lupancu2023,
  author = {Lupancu, Tanya J and Eivazitork, Mahtab and Hamilton, John A and Achuthan, Adrian A and Lee, Kevin M-C},
  title = {CCL17 / TARC in autoimmunity and inflammation—not just a T‐cell chemokine},
  journal = {Immunology & Cell Biology},
  year = {2023},
  doi = {10.1111/imcb.12644}
}
Start for free →